International Journal of Endocrinology / 2016 / Article / Tab 1

Research Article

Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population

Table 1

Baseline demographic data.


Age 22353.7 (51.8, 55.6)

Gender 223F184 (82.5%)
M39 (17.5%)

Ethnicity213Māori71 (31.9%)
NMāori142 (63.6%)

Diagnosis 223Graves’s142 (63.6%)
TMNG75 (33.6%)
STA6 (3.7%)

Median weight (kg)20874.6 (52.2, 118.8)

Ophthalmopathy 140Nil103 (73.57%)
Mild26 (18.57%)
Mod.7 (5.00%)
Sev.4 (2.86%)

T4 at presentation21029 (12, 65.4)

Pretreatment ATD223184 (86.4%)

Length of ATD (wks) 19349 (13, 439)

Posttreatment ATD 19274 (38.54%)

Length of FU (wks)223913 (432, 1466)

ATD: antithyroid medication; F: female; M: male; NMāori: non-Māori; GD: Graves’s disease; TMNG: toxic multinodular goitre; STA: solitary toxic adenoma; Mod.: moderate eye disease; Sev.: severe eye disease.
Continuous variables are expressed as mean (95% confidence intervals) or median (5th, 95th percentile) according to their distribution. Categorical variables are expressed as number (percentage).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.